Intarcia Therapeutics

February 26, 2020

Go or no go? Ozanimod and Fintepla await FDA verdicts

Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.

Are small companies carrying the complete response letter can?

July 12, 2017

Venture financing still positive but big rounds less common

The trend for VCs to pile in to bigger, later rounds might just be weakening.

May 23, 2017

Healthcare unicorns and where to find them

February 07, 2017

With creativity it still makes sense to turn royalties into cash

January 16, 2017

Chasing ever bigger, ever fewer venture rounds

January 03, 2017

Pharma business development news over Christmas

December 12, 2016

Oxford Nanopore squares up to Illumina's sequencing might

October 18, 2016

Biotech venture funding shrinks as post-boom shape emerges

September 16, 2016

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

May 11, 2016

Now what for Intarcia with clinical work done?

Load More